1. Introduction {#sec1}
===============

Lung cancer is the leading cause of cancer related mortality worldwide. Over 80% of lung cancer can be attributed to cigarette smoking \[[@B1]\]. However, Only 10% to 15% of chronic smokers develop lung cancer, indicating that other factors (e.g., genetic factors) might also play a pivotal role in lung cancer risk \[[@B2]\]. Recently, genome-wide association studies have discovered dozens of loci that are related to lung cancer risk \[[@B3]--[@B11]\]. These loci only account for a small fraction of the risk of developing lung cancer due to the stringent screening criteria of GWAS \[[@B8]\]. Thus, an effort on candidate gene strategies might help to explain the missing heritability.

The Pit-Oct-Unc (POU) homeodomain transcription factor, POU5F1 (also known as OCT-3, OCT-4, and OCT 3/4), is a key regulator of self-renewal and differentiation in embryonic stem cells \[[@B12]--[@B15]\].*POU5F1* gene expresses in adult human stem cells, immortalized nontumorigenic cells, and tumor cells and cell lines, and its level decreases with the onset of differentiation and loss of pluripotency in these cells \[[@B16]--[@B18]\]. According to the cancer stem cell (CSC) dogma, the reactivation of early embryonic stem cell genes such as*POU5F1* in somatic stem cells and/or differentiating progenitor cells may lead to transformation into CSCs, which may result in cancer initiation, promotion, and progression \[[@B19]--[@B21]\]. To date, high expression level of POU5F1 has been detected in various types of cancer cells \[[@B22], [@B23]\]. In particular, Karoubi et al. observed higher levels of expression of*POU5F1* gene and atypical cytoplasmic distribution of POU5F1 in lung adenocarcinoma cell lines, indicating an oncogenic role in lung adenocarcinoma \[[@B24]\]. Polymorphisms in POU class 5 homeobox 1 pseudogene 1 gene (*POU5F1P1*), a highly homologous pseudogene of*POU5F1*, were identified to be associated with the risk of gastric cancer \[[@B25]\]. Therefore, we postulated that potentially functional genetic variation within*POU5F1* might modify the susceptibility to lung cancer. To test this hypothesis, we conducted a case-control study including 1,341 cases and 1,982 controls to investigate the association between functional polymorphisms in*POU5F1* and lung cancer risk.

2. Materials and Methods {#sec2}
========================

2.1. Study Subjects {#sec2.1}
-------------------

This case-control study was approved by the institutional review board of Nanjing Medical University. Cases were recruited from the Cancer Hospital of Jiangsu Province and the First Affiliated Hospital of Nanjing Medical University since 2003. Patients with histopathologically confirmed incident lung cancer were included. Exclusion criteria include having a prior history of other cancers, having metastatic cancer from other sites, or having undergone chemotherapy of radiotherapy. Controls were randomly selected from individuals participating in a community based noninfectious disease screening program in Jiangsu Province during the same time period. The controls were cancer-free and were frequency matched to cases by age and sex. We enrolled 1,341 cases and 1,982 controls in the final set. After providing a written informed consent, participants donated 5 mL venous blood sample and underwent a face-to-face interview that solicited information on participants\' demographics (e.g., age and sex) and health related behaviors (e.g., smoking).

Those who had smoked one cigarette or more per day for \>1 year were considered as smokers; smokers who had quit smoking for \>1 year were defined as former smokers; all others were classified as never smokers \[[@B6]\]. Smoking dosage were measured by pack-years of smoking \[(cigarettes per day/20) × smoking years\]. In addition, smokers were divided into light and heavy smokers according to the threshold of 25 pack-years.

2.2. SNP Selection {#sec2.2}
------------------

All SNPs in the*POU5F1* gene region and 10 kb upstream were screened based on the Han Chinese population (CHB) of the HapMap Project \[HapMap Data Rel. 27 Phase II + III\]. Minor allele frequency (MAF) ≥ 0.05 was used to filter low-frequency variants. The remaining variants were annotated by SNPinfo Web Server (<http://snpinfo.niehs.nih.gov/>); 27 SNPs were selected as potentially functional variants. We then performed linkage disequilibrium (LD) analysis with an *r* ^2^ threshold of 0.8; 19 SNPs were retained for genotyping. However, rs1265163 and rs3132517 were excluded because of probe design failure. Therefore, there were 17 SNPs included in the final set ([Table 2](#tab2){ref-type="table"}).

2.3. Genotyping {#sec2.3}
---------------

Genomic DNA was extracted from a leukocyte pellet by proteinase K digestion, followed by phenol-chloroform extraction and ethanol precipitation. Illumina Infinium BeadChip (Illumina Inc.) was used for genotyping and GenTrain version 1.0 clustering algorithm in GenomeStudio V2011.1 (Illumina Inc.) for genotype calling. Technicians performing the genotyping were blinded to the case or control status of participants.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Deviation of genotype distribution for each SNP from the Hardy-Weinberg equilibrium was tested by a goodness-of-fit *χ* ^2^. Student\'s *t* test for continuous variables and *χ* ^2^ test for categorical variables were applied for analyzing distribution differences of demographic characteristics and genotypes between cases and controls. The association between SNPs and lung cancer risk was examined under an additive model using logistic regression to estimate odds ratios (ORs) \[[@B26]\] and 95% confidence intervals (CIs) with adjustment for age, sex, and pack-years of smoking when appropriate. We used *χ* ^2^-based *Q*-test to test the heterogeneity from corresponding subgroups. Multiplicative interactions were tested using a general logistic regression model by applying the equation$$\begin{matrix}
{Y = \beta_{0} + \beta_{G}G + \beta_{E}S + \beta_{GS}\left( { GS} \right) + \sum\beta_{i}{Covar}_{i},} \\
\end{matrix}$$where *Y* is the logit of case-control status, *G* and *S* are factors (SNP or smoking status), *β* ~0~ is constant, *β* ~*G*~ and *β* ~*S*~ are the main effects of factors *G* and *S*, respectively. And *β* ~*GS*~ is the interaction term. Covar~*i*~ denote covariates for adjustment, including age and sex.

All analyses were performed using R software (version 3.1.1, The R Foundation for Statistical Computing, <http://www.cran.r-project.org/>).

3. Results {#sec3}
==========

The geographic characteristics of participants were summarized in [Table 1](#tab1){ref-type="table"}. The distributions of age (*P* = 0.980) and sex (*P* = 0.179) were comparable between cases and controls. However, cases have larger proportions of smokers and heavy smokers than controls (*P* \< 0.001). 481 (35.87%) cases had squamous cell carcinoma and 860 (64.13%) cases had adenocarcinoma.

The call rates of genotyping for 17 SNPs were all above 98% ([Table 2](#tab2){ref-type="table"}). The observed genotypes for these SNPs were in agreement with Hardy-Weinberg equilibrium among controls. The variant alleles of 2 SNPs (rs887468 and rs3130457) were significantly associated with increased risk of lung cancer after multiple comparison (OR = 1.29, 95% CI: 1.11--1.51, *P* ~fdr~ = 0.017 for rs887468; OR = 1.29, 95% CI: 1.10--1.51, *P* ~fdr~ = 0.034 for rs3130457, resp.) (Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}). However, no significant associations were detected from other SNPs.

To further examine the associations of these 2 SNPs with lung cancer risk, we conducted stratified analyses within subgroups according to selected variables ([Table 4](#tab4){ref-type="table"}). As a whole, the devastating effect of variant alleles was more pronounced in elder age group (\>60), males, never smokers, and adenocarcinoma patients. No significant heterogeneity was found for ORs and their 95% CIs between different subgroups. We also explored interaction between these SNPs and smoking status. As shown in [Table 5](#tab5){ref-type="table"}, an interaction existed between the genotype of rs887468 and smoking status (*P* for multiplicative interaction = 0.017). However, no significant multiplicative interaction was observed for rs3130457 (data not shown). Furthermore, we investigated cumulative effect of these 2 risk alleles on lung cancer and observed significant allele-dosage association between number of risk alleles and lung cancer risk (*P* ~trend~ \< 0.001). People who carried one or two risk alleles were 1.33 times more likely to develop lung cancer than those who carried no risk allele, and those with more than two risk alleles were 1.46 times more likely to develop lung cancer. These data indicated that those who carried more risk alleles had a higher risk of lung cancer.

4. Discussion {#sec4}
=============

In the current study, we explored the association of 17 potentially functional SNPs in*POU5F1* gene with the development of lung cancer in 1,341 cases and 1,982 healthy controls. We found that the variant allele of rs887468 and rs1310457 were associated with increased lung cancer risk. To the best of our knowledge, it is the first association study of polymorphisms in the*POU5F1* gene and lung cancer, which provides more evidence for understanding the role of*POU5F1* in lung cancer risk.

POU5F1, a transcription factor, is involved in regulation of pluripotent state of stem cells, and its level decreases with the onset of differentiation in these cells \[[@B15]--[@B18]\]. Amini et al. have found that cancer cell lines and cancer tissues had significantly higher expression levels of early embryonic stem cell genes, including*POU5F1*,*SOX2*, and*CD133* \[[@B21]\]. In the hypoxia conditions, POU5F1 can promote*CD133* expression in the lung cancer cells, which is a specific cell surface marker for cancer stem cells \[[@B27]\]. In addition, parallel elevated expression of*POU5F1* and*Nanog* in lung adenocarcinoma (LAC) increases the percentage of*CD133*-expressing subpopulation, enhances drug resistance, and promotes epithelial-mesenchymal transition (EMT); coexpression also activates*Slug* and enhances the tumor-initiating capability of LAC \[[@B28], [@B29]\]. Furthermore, knockdown of*POU5F1* impeded tumorigenic and metastatic ability and reversed the EMT process of lung adenocarcinoma \[[@B28], [@B29]\]. For squamous cell carcinoma, Chen et al. measured*POU5F1* expression in nonsmall cell lung cancer tissues and found that although the proportion of squamous cell carcinoma tissues which have elevated expression was smaller than that of adenocarcinoma, the increased expression of*POU5F1* was associated with poor differentiation of cancer cells and shorter overall survival in both histologic subtype of lung cancer \[[@B30]\]. Taken together,*POU5F1* expression is crucial for the self-renewal and oncogenic potentials of lung cancer stem cells. Our findings further demonstrated that*POU5F1* might be a susceptibility gene of lung cancer, which was consistent with the observations mentioned above.

The two SNPs, rs887468 and rs3130457, are located in the upstream region from the transcription starting site of*POU5F1* gene. According to a web-based SNP analysis tool, SNPinfo (<http://snpinfo.niehs.nih.gov/>), the two SNPs are all potential transcriptor binding sites and the SNP rs887468 may influence an exonic splicing enhancer \[[@B31]\] or exonic splicing silencer (ESS) (Supplemental Table 1) (see Supplementary Material available online at <http://dx.doi.org/10.1155/2015/851320>). Variations in ESE or ESS can be involved in disruptions of balanced interplay of ESE- and ESS-binding proteins, which thereby results in missplicing and causes deficiency in expression products of nearby genes \[[@B31]--[@B34]\]. We speculate that variant genotype of rs887468 might lead to alternative splicing events and disequilibrium for different isoforms of*POU5F1*, suggesting a biological plausible mechanism for lung cancer risk. Variation in rs887468 may influence its interactions with transcription factors such as Myc-associated zinc-finger protein (MAZ) (as predicted by RegulomeDB (<http://www.regulomedb.org/>)).*MAZ* gene normally expresses in the lungs \[[@B35]\]. It is responsible for regulation of oncogene transcription from promoter \[[@B36]\]. One possible explanation for the association between rs887468 and lung cancer risk might be that the variant genotype alters interactions of the loci with transcription factors and results in aberration in function of*POU5F1* gene and elicits procedure of carcinogenesis.

Based on an online tool, DNase-seq and RegulomeDB (<http://www.regulomedb.org/>), rs887468 and rs3130457 fall into DNase I peaks. DNase I hypersensitivity regions are potential genetic regulatory loci and correlate with binding sites of sequence-specific DNA-binding proteins \[[@B39]\]. This suggests a possible mechanism for the effect of these variants on lung cancer risk. Additionally, a multiplicative interaction was observed between rs887468 in*POU5F1* gene and smoking status. The interaction result indicated that the harmful effect of variant allele of rs887468 was weaker among current smokers. However, our results are very preliminary; further experimental studies are warranted to uncover the underling mechanism of these observations.

In summary, our case-control study reported 2 potential functional SNPs in*POU5F1* gene that may affect the risk for lung cancer in a Chinese population. Given that our results are very preliminary, more large scale studies are required to validate our findings in diverse ethnic populations and clarify the molecular basis behind these observations.

Supplementary Material {#supplementary-material-sec}
======================

###### 

To search for potentially functional variation, common SNPs in POU5F1 were annotated by SNPinfo Web Server (). Among the 17 genotyped SNPs, 14 SNPs are located in transcription factor binding sites, 7 SNPs are exonic splicing enhancer (ESE) or exonic splicing silencer (ESS). Functional annotation of the 17 genotyped SNPs are summarized in Supplementary Table 1.
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###### 

Distributions of select variables in lung cancer cases and cancer-free controls.

  Variables                  Case (*N* = 1,341)   Control (*N* = 1,982)   *P*
  -------------------------- -------------------- ----------------------- -------------
  Age (mean ± sd.)           61.06 ± 10.15        61.32 ± 11.07           0.473
   ≤60                       596 (44.44%)         883 (44.55%)            0.980
   \>60                      745 (55.56%)         1099 (55.45%)           
  Gender                                                                   
   Male                      949 (70.77%)         1358 (68.52%)           0.179
   Female                    392 (29.23%)         624 (31.48%)            
  Smoking status                                                           
   Current                   634 (47.28%)         876 (44.20%)            **\<0.001**
   Former                    185 (13.80%)         86 (4.34%)              
   Never                     522 (38.92%)         1020 (51.46%)           
  Pack-year (py.)                                                          
   ≤25                       774 (57.72%)         1505 (75.93%)           **\<0.001**
   \>25                      567 (42.28%)         477 (24.07%)            
  Histology type                                                           
   Squamous cell carcinoma   481 (35.87%)                                  
   Adenocarcinoma            860 (64.13%)                                  

###### 

Summary of associations between 17 SNPs in selected *POU5F1* gene with lung cancer risk.

  SNP             Allele^a^   Case^b^           Control^b^        Call rate (%)   MAF (case/control)^c^   HWE^d^     OR (95% CI)^e^          *P* ^e^     *P* ^f^
  --------------- ----------- ----------------- ----------------- --------------- ----------------------- ---------- ----------------------- ----------- -----------
  **rs887468**    **G/A**     **997/322/22**    **1588/368/26**   **100.00**      **0.14/0.11**           **0.35**   **1.29 (1.11--1.51)**   **0.001**   **0.017**
  **rs3130457**   **A/G**     **1030/293/18**   **1626/335/21**   **100.00**      **0.12/0.10**           **0.43**   **1.29 (1.10--1.51)**   **0.002**   **0.034**
  rs12215963      A/G         1102/221/8        1694/254/9        98.95           0.09/0.07               1.00       1.26 (1.05, 1.53)       0.015       0.255
  rs885948        A/G         321/665/355       530/1000/452      100.00          0.51/0.48               0.65       1.13 (1.02, 1.25)       0.022       0.374
  rs4713438       G/A         978/335/28        1391/552/39       100.00          0.15/0.16               0.07       0.90 (0.78, 1.04)       0.169       1.000
  rs2269713       A/G         875/411/55        1337/579/66       100.00          0.19/0.18               0.70       1.09 (0.96, 1.24)       0.181       1.000
  rs1052989       G/A         556/611/174       772/931/279       100.00          0.36/0.38               0.96       0.93 (0.84, 1.04)       0.201       1.000
  rs885950        A/C         463/636/241       722/930/322       99.73           0.42/0.40               0.45       1.07 (0.96, 1.18)       0.208       1.000
  rs879882        A/G         342/676/323       553/964/465       100.00          0.49/0.48               0.26       1.06 (0.96, 1.18)       0.227       1.000
  rs2394882       C/A         617/577/147       851/914/217       100.00          0.32/0.34               0.23       0.94 (0.84, 1.04)       0.239       1.000
  rs9468877       G/A         1141/193/7        1718/256/8        100.00          0.08/0.07               0.86       1.12 (0.92, 1.35)       0.275       1.000
  rs1108746       C/A         1097/233/11       1607/356/19       100.00          0.10/0.10               1.00       0.95 (0.80, 1.12)       0.541       1.000
  rs1265156       C/A         589/579/173       835/900/247       100.00          0.34/0.35               0.84       0.97 (0.88, 1.08)       0.597       1.000
  rs887464        G/A         487/628/226       684/963/335       100.00          0.40/0.41               0.93       0.97 (0.88, 1.08)       0.625       1.000
  rs3130503       G/A         791/485/65        1154/726/102      100.00          0.23/0.23               0.42       0.98 (0.87, 1.11)       0.773       1.000
  rs3094188       A/C         834/452/55        1250/650/82       100.00          0.21/0.21               0.89       1.02 (0.90, 1.15)       0.775       1.000
  rs887466        G/A         403/656/281       587/981/413       99.94           0.45/0.46               0.93       1.00 (0.90, 1.10)       0.955       1.000

^a^Major/minor allele. ^b^Major homozygote/heterozygote/rare homozygote between cases and controls. ^c^Minor allele frequency. ^d^Hardy-Weinberg equilibrium test among controls.

^e^Logistic regression with adjustment for age, sex, and pack-year of smoking in additive model.

^f^ *P* values of false discovery rate (FDR).

###### 

Associations between 2 functional SNPs in *POU5F1* gene with lung cancer risk.

  Genotype              Case (*N* = 1,341)   Control (*N* = 1,982)   OR (95% CI)^b^      *P* ^b^
  --------------------- -------------------- ----------------------- ------------------- -----------
  rs887468 (G\>A)^a^                                                                      
   GG                   997                  1588                    1.00                 
   GA                   322                  368                     1.33 (1.12--1.59)   **0.001**
   AA                   22                   26                      1.39 (0.78--2.49)   0.269
   Additive model       1341                 1982                    1.29 (1.11--1.51)   **0.001**
  rs3130457 (A\>G)^a^                                                                     
   AA                   1030                 1626                    1.00                 
   AG                   293                  335                     1.31 (1.10--1.57)   **0.003**
   GG                   18                   21                      1.44 (0.76--2.76)   0.265
   Additive model       1341                 1982                    1.29 (1.10--1.51)   **0.002**

^a^Major allele \> Minor allele. ^b^Logistic regression with adjustment for age, gender, and pack-years of smoking.

###### 

Stratified analysis on the associations of rs887468 and rs3130457 in *POU5F1* with lung cancer risk.

  Characteristics            rs887468 (G\>A)   *P* ~het~ ^c^   rs3130457 (A\>G)    *P* ~het~ ^c^                                                                                  
  -------------------------- ----------------- --------------- ------------------- --------------- ------------ ------------- ------------------- ------------------- ----------- -------
  Age                                                                                              0.093                                                                          0.079
   ≤60                       450/136/10        689/185/9       1.11 (0.88--1.40)   0.392                        463/124/9     705/170/8           1.09 (0.85--1.38)   0.498        
   \>60                      547/186/12        899/183/17      1.45 (1.18--1.79)   **\<0.001**     567/169/9    921/165/13    1.46 (1.17--1.82)   **\<0.001**                     
  Gender                                                                                           0.749                                                                          0.398
   Male                      712/222/15        1100/241/17     1.32 (1.09--1.59)   **0.004**                    734/200/15    1126/219/13         1.35 (1.11--1.64)   **0.003**    
   Female                    285/100/7         488/127/9       1.25 (0.95--1.65)   0.105           296/93/3     500/116/8     1.16 (0.87--1.56)   0.312                           
  Smoking status                                                                                   0.170                                                                          0.455
   Current                   493/133/8         697/166/13      1.08 (0.86--1.36)   0.511                        503/124/7     715/152/9           1.14 (0.89--1.44)   0.296        
   Former                    127/52/6          66/19/1         1.54 (0.9--2.64)    0.114           135/44/6     69/16/1       1.53 (0.87--2.68)   0.136                           
   Never                     377/137/8         825/183/12      1.44 (1.14--1.81)   **0.002**       392/125/5    842/167/11    1.37 (1.07--1.75)   **0.011**                       
  Pack-years                                                                                       0.331                                                                          0.680
   0                         377/137/8         825/183/12      1.44 (1.14--1.81)   **0.002**                    392/125/5     842/167/11          1.37 (1.07--1.75)   **0.011**    
   0--25                     193/53/6          393/85/7        1.21 (0.86--1.70)   0.270           200/47/5     403/76/6      1.19 (0.83--1.70)   0.336                           
   \>25                      427/132/8         370/100/7       1.11 (0.86--1.45)   0.422           438/121/8    381/92/4      1.18 (0.90--1.56)   0.231                           
  Histology type                                                                                   0.198                                                                          0.285
   Squamous cell carcinoma   370/103/8         1588/368/26     1.12 (0.88--1.42)   0.358                        381/92/8      1626/335/21         1.14 (0.88--1.46)   0.319        
   Adenocarcinoma            627/219/14        1588/368/26     1.36 (1.15--1.62)   **\<0.001**     649/201/10   1626/335/21   1.35 (1.13--1.62)   **0.001**                       

^a^Wild-type homozygote/heterozygote/variant homozygote. ^b^Adjusted for age, gender, and pack-years of smoking where appropriate in additive model. ^c^ *P* for heterogeneity.

###### 

The interaction between rs887468 and smoking status on lung cancer risk.

  Smoking status                       rs887468   OR (95% CI)^a^   *P* ^a^                       
  ------------------------------------ ---------- ---------------- --------- ------------------- -------------
  Nonsmokers                           GG         504              891       1.00                 
  Nonsmokers                           GA/AA      203              215       1.67 (1.34--2.08)   **\<0.001**
  Smokers                              GG         493              697       1.21 (1.01--1.46)   **0.039**
  Smokers                              GA/AA      141              179       1.35 (1.04--1.76)   **0.024**
  *P* for multiplicative interaction              **0.017**                                      

^a^ *P* value of interaction analysis between rs887468 and pack-years of smoking on lung cancer risk with adjustment for age and gender.
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